Liu Tianshi: Difference between revisions
From Bioblast
No edit summary |
No edit summary |
||
Line 3: | Line 3: | ||
|firstname=Liu | |firstname=Liu | ||
|title=PhD | |title=PhD | ||
|institution=[[File:Tianshi Liu.jpeg|right|150px|Tianshi Liu]] Lund University, Β | |institution=[[File:Tianshi Liu.jpeg|right|150px|Tianshi Liu]] Β | ||
Lund University, <br> | |||
Mitochondrial Medicine, SE | Mitochondrial Medicine, SE |
Revision as of 13:07, 19 April 2023
Name | Tianshi Liu, PhD |
---|---|
Institution |
Lund University, Mitochondrial Medicine, SE |
Address | BMC A13, SΓΆlvegatan 17, SE-221 84 |
City | Lund |
State/Province | |
Country | Sweden |
[email protected] | |
Weblink | |
O2k-Network Lab |
Labels:
Publications
Published | Reference | |
---|---|---|
Shao 2019 Cardiovasc Diabetol | 2019 | Shao Q, Meng L, Lee S, Tse G, Gong M, Zhang Z, Zhao J, Zhao Y, Li G, Liu T (2019) Empagliflozin, a sodium glucose co-transporter-2 inhibitor, alleviates atrial remodeling and improves mitochondrial function in high-fat diet/streptozotocin-induce diabetic rats. Cardiovasc Diabetol 18:165. |
Zhang 2018 Cardiovasc Diabetol | 2018 | Zhang X, Zhang Z, Yang Y, Suo Y, Liu R, Qiu J, Zhao Y, Jiang N, Liu C, Tse G, Li G, Liu T (2018) Alogliptin prevents diastolic dysfunction and preserves left ventricular mitochondrial function in diabetic rabbits. Cardiovasc Diabetol 17:160. |
Zhang 2017 J Am Heart Assoc | 2017 | Zhang X, Zhang Z, Zhao Y, Jiang N, Qiu J, Yang Y, Li J, Liang X, Wang X, Tse G, Li G, Liu T (2017) Alogliptin, a dipeptidyl peptidase-4 inhibitor, alleviates atrial remodeling and improves mitochondrial function and biogenesis in diabetic rabbits. J Am Heart Assoc 6:e005945. |